Clinical observation of bevacizumab combined with XELOX chemotherapy in the treatment of advanced colorectal cancer
Objective To explore the efficacy of bevacizumab combined with capecitabine(XELOX)chemotherapy in the treatment of advanced colorectal cancer(CRC).Methods 92 patients with advanced CRC were randomly divided into an observation group(48 cases)and a control group(44 cases).The control group was given XELOX chemotherapy,and the observation group was treated with bevacizumab on the basis of the control group.The clinical efficacy,tumor markers[carbohydrate antigen 242(CA242),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)]before and after treatment,and adverse reactions(dizziness,anorexia,abdominal distension,vomiting)were compared between the two groups.Results After treatment,the observation group had objective remission rate of 31.25%and disease control rate of 70.83%,which were significantly higher than 13.64%and 50.00%in the control group(P<0.05).After treatment,in the observation group,CA242 was(34.38±3.16)IU/ml,CEA was(19.94±1.15)μg/L and CA199 was(33.52±3.25)U/ml;in the control group,CA242 was(44.24±4.23)IU/ml,CEA was(31.14±1.33)μg/L,and CA199 was(58.16±3.32)U/ml.After treatment,the levels of CA242,CEA and CA199 in both groups were significantly decreased compared with those before treatment,and the decrease range in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of bevacizumab with XELOX chemotherapy can significantly improve the clinical efficacy of patients with advanced CRC,and at the same time help to reduce the expression of serum CA242,CEA,CA199 in vivo,improve the rate of disease remission and control rate.Meanwhile,compared with XELOX chemotherapy alone,there is no significant increase in adverse reactions,and it is safe and reliable.
NETL
NSTL
万方数据
